Richard S. Irwin, MD, FCCP; and Naomi D. Richardson, MSc, MBA

Size: px
Start display at page:

Download "Richard S. Irwin, MD, FCCP; and Naomi D. Richardson, MSc, MBA"

Transcription

1 Supplement DECREASING THE GLOBAL BURDEN OF ASTHMA Side Effects With Inhaled Corticosteroids* The Physician s Perception Richard S. Irwin, MD, FCCP; and Naomi D. Richardson, MSc, MBA The National Asthma Education and Prevention Program 1997 guidelines and 2002 update provide an overview of potential local and systemic side effects associated with inhaled corticosteroids (ICS) and suggest ways of minimizing the risk of these side effects occurring. Despite the guidelines and extensive clinical experience of the safe use of ICS, a significant number of physicians retain concerns regarding side effects. Local side effects may lead to patients discontinuing therapy, with or without the knowledge of their physicians. In particular, concerns regarding systemic side effects, such as growth retardation in children and osteoporosis, remain relatively widespread. Pharmacokinetic studies reveal that different ICS compounds and formulations result in different degrees of systemic bioavailability, indicating possible differences in their potential to cause systemic side effects. However, clinical studies that can be used to differentiate between ICS formulations are generally lacking. Consequently, there is a need to continue to further our understanding of side effects with ICS, with the aim of identifying formulations, devices, and doses with an optimal risk/benefit ratio. The introduction of new agents with potentially improved safety profiles may reassure physicians and patients as to the relative benefits of ICS therapy in asthma. (CHEST 2006; 130:41S 53S) Key words: adverse events; asthma; inhaled corticosteroids; safety; side effects Abbreviations: BDP beclomethasone dipropionate; BUD budesonide; CFC chlorofluorocarbon; CI confidence interval; CIC ciclesonide; DPI dry powder inhaler; FLU flunisolide; FP fluticasone propionate; HFA hydrofluoroalkane; ICS inhaled corticosteroids/corticosteroid; MF mometasone furoate; NAEPP National Asthma Education and Prevention Program; pmdi pressurized metered-dose inhaler; RR relative risk; TAA triamcinolone acetonide *From the Pulmonary, Allergy and Critical Care Medicine Division (Dr. Irwin), University of Massachusetts Medical School, Worcester, MA; and Magenta Communications Ltd, (Ms. Richardson), Oxon, UK. Dr. Irwin has no potential personal or financial conflict of interest to disclose. Ms. Richardson discloses that she was contracted to provide author support and manuscript preparation by Boom- Com Communications Inc., Denver, CO. BoomCom Communications, Inc., was engaged by Altana Pharma, the sponsors of this supplement. Inhaled corticosteroids (ICS) are the cornerstone of asthma management and result in improved symptom control and quality of life for many patients. 1 However, as for all medicines, the physician must achieve a balance between the potential benefits for the patient and the risk of side effects. For Manuscript received July 2, 2005; revision accepted March 20, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( org/misc/reprints.shtml). Correspondence to: Richard S. Irwin, MD, FCCP, Pulmonary, Allergy and Critical Care Medicine Division, University of Massachusetts Medical School, 55 Lake Ave North, Worcester, MA 01655; Irwinr@ummhc.org DOI: /chest.130.1_suppl.41S CHEST / 130 / 1/ JULY, 2006 SUPPLEMENT 41S

2 ICS therapy, the potential side effects may be local in the oropharyngeal cavity, or systemic due to absorption of ICS into the circulation through the lungs and GI tract. Increasing the dose of ICS in order to achieve improvements in asthma symptoms, or prolonged treatment over many years, will expose patients to an increased risk of side effects. 1 Despite the publication of guidelines 2,3 stressing the importance of ICS, ICS are often underused. The major reason that physicians fail to prescribe ICS appears to be due to disagreement with recommendations, particularly regarding when the balance lies between their benefits and the risk of complications and side effects. 3 In addition, patients fears of ICS may lead to a lack of adherence with prescribed therapy, which may expose them to the unnecessary risk of an asthma exacerbation. 3 Although the nature of local side effects with ICS is fairly well described and understood, 1 the impact of these side effects on patient quality of life and adherence to therapy may be underestimated. 4 However, the most common concerns regarding ICS therapy relate to the potential systemic effects, which are often more serious, long term, and can be difficult to detect and treat. 5,6 preventing an exacerbation. The authors 15 calculated the number of patients that needed to be treated to prevent withdrawal of therapy due to worsening of asthma symptoms vs the risk of oral candidiasis. In this analysis, the number of patients who avoided asthma exacerbation by taking FP increased with increasing daily doses of FP, although the doseresponse curve was relatively flat, with little benefit in efficacy between FP at 500 g and 1,000 g. 15 However, as the dose of FP increased, so did the risk of oral candidiasis. At a dose of 100 g, the difference between the number of additional patients that would need to be treated to avoid a loss of efficacy vs the number of patients that would need to be treated in order to see an additional case of oral candidiasis Local Side Effects of ICS Therapy The National Asthma Education and Prevention Program (NAEPP) 1997 guidelines for the diagnosis and management of asthma list local side effects with ICS as oral candidiasis, dysphonia, and cough. 1 Oral candidiasis is a common side effect for many adult patients receiving ICS. 1 The reported incidence varies from 0 to 77%, based on how oral candidiasis was defined. 7 Systematic reviews 8 10 have yielded conflicting information. For example, some reviews 8 10 have found that fluticasone propionate (FP), but not budesonide (BUD), was associated with an increased risk of candidiasis compared with placebo, and this effect was dose related. However, in a similar review 11 of comparative studies between FP vs BUD or beclomethasone dipropionate (BDP), there was no difference in the risk of oral candidiasis between these agents. Oral candidiasis was more frequent with FP at 880 g/d (5.2%) than with ciclesonide (CIC) at 640 g/d (0.4%; p ). 12 In a study 13 of mometasone furoate (MF) at 200 g and 400 g bid compared with the BUD inhaler (Turbuhaler; AstraZeneca AB; Södertälje, Sweden), 400 g bid, the incidence of oral candidiasis was not more than 3% in any group. However, at higher doses of MF (800 to 1,600 g/d), oral candidiasis has been observed in 20 to 23% of patients. 14 A systematic review 15 compared the dose response for oral candidiasis for FP with the dose response for Figure 1. Comparison of the relative effects of increasing FP dose in asthma on the number of patients needed to be treated for an additional patient to benefit (NNT) vs the number of patients needed to receive an intervention for an additional patient to experience harm (NNH), in this case oral candidiasis. Reproduced with permission from Powell and Gibson S Decreasing the Global Burden of Asthma

3 was 87 patients (Fig 1). 15 In comparison, at an FP dose of 1,000 g, this difference had fallen to 21 patients, a narrow margin of tolerability (Fig 1). 15 Thus, when increasing the dose of FP, the risk of oral candidiasis will increase much faster than the risk of an exacerbation will decrease. Esophageal candidiasis due to ICS was not mentioned in the NAEPP guidelines and was thought to be uncommon. However, utilizing upper-gi endoscopy, Kanda et al 16 reported a prevalence for this side effect of 37% in 49 patients receiving FP vs 0.3% for 700 control patients. Of the patients receiving FP, 36 were asthmatic and 13 had COPD; they had been receiving FP for a mean of ( SD) weeks (range, 5 to 42 weeks) at doses from 200 to 1,200 g/d. 16 Although five patients had diabetes, there was no evidence of immunosuppression in any of the patients. The frequency of esophageal candidiasis was dose related, present in 40%, 19%, and 75% of patients receiving FP doses of 600, 800, and 1,200 g/d, respectively (p 0.05 for 1,200 g vs800 g or 600 g). 16 A reduction in daily dose of FP from 1,200 or 800 g to800 g or 600 g, respectively, resolved the infection in four of five patients after 1 month. 16 Esophageal candidiasis was also more frequent in patients with diabetes (29.5% without vs 100% with diabetes, p 0.01). 16 High-grade esophageal candidiasis with white moss was found by Shuto et al 17 during GI endoscopy in two asthma patients receiving ICS. As a follow-up, Shuto et al 17 examined 20 asthmatic patients who had been receiving long-term FP inhalation. Thirty-five percent of these patients had esophageal candidiasis, 43% had grade 1, 14% had grade 2, and 43% had grade The authors 17 also showed that immediately after inhalation of 200 g of FP, there were significant amounts of FP in the esophagus (3.3 g). 17 Even after 30 min, FP remained detectable and the amount of drug recovered was affected by whether the patient was prone or remained upright (0.67 g if the patient laid down immediately or 0.11 g if they remained standing). 17 This study implies that if asthmatic patients do not go to sleep immediately after FP inhalation, the remaining FP in the esophagus decreases rapidly, thereby decreasing the risk of esophageal candidiasis. 17 In addition, by changing the FP inhalation times to before breakfast and dinner, the remaining FP in the esophagus would be removed by the passage of food and would not remain in the esophagus. 17 Thus, physicians need to be aware of the possibility of esophageal candidiasis with FP therapy and advise patients on how to potentially minimize their risk for this side effect. 17 Dysphonia or hoarseness, cough, and pharyngitis have also been reported with ICS use. Dysphonia is observed in 5 to 50% of patients receiving ICS. 1 Dysphonia appears to be a direct effect of the corticosteroid, as dysphonia was absent when the propellant or excipients were administered without ICS. 18 Dysphonia was associated with vocal stress and increasing dosages of ICS 18 and was more frequently observed in patients using a spacer device. 7,19 Compared with placebo, there were no differences in the rates of dysphonia with MF (100, 200, and 400 g bid) or BDP at 168 g bid (frequency of dysphonia was 1 to 3%). 20 However, at doses of MF between 800 g and 1,600 g,7to12% of patients reported dysphonia. 14 Cough during ICS inhalation has been reported in 34% of adults, with no difference in the incidence of this side effect between BDP and BUD. 21 While the risk of oropharyngeal soreness/hoarseness reported for adults in systematic reviews with BUD was no different than with placebo, it was increased with FP dose. 9,10 Moreover, the incidence of hoarseness was 4% in patients receiving FP at 220 g bid vs 1% for triamcinolone acetonide (TAA) at 600 g bid over 12 weeks. 22 Although hoarseness was lower with CIC at 640 g/d (2.4%) compared with FP at 880 g/d (4.6%), this difference was not significant (p 0.07), 12 and there was no significant difference between the two groups in the frequency of pharyngitis (4.1% vs 5.4%, respectively; p 0.28). 12 In a systematic review 11 of comparative studies, pharyngitis was more likely with FP at twice the dose of BDPorBUD. Similar findings for local side effects are seen for ICS/long-acting -agonist combination therapies. With BUD/formoterol, pharyngitis was seen in 6% of patients in clinical trials, with coughing in 5%. 23 For FP/salmeterol, oropharyngeal candidiasis was seen in 2 to 4% of patients, hoarseness/dysphonia in 2 to 4%, throat irritation in 1 to 3%, and cough/breathing difficulties in 1 to 3%. 24 In a comparative study 25 of FP/salmeterol vs FP vs salmeterol vs placebo, there was no difference in the incidence of side effects between the ICS groups and the salmeterol group, except for a higher incidence of oral candidiasis for FP/salmeterol (10%) or FP alone (6%) vs salmeterol (3%) and placebo ( 1%). Local Side Effects in Children Studies on local side effects in children are less common than for adults. 7 However, a relatively large, prospective, observational, cross-sectional cohort study 7 of 639 patients ( months old) with moderate-to-severe asthma showed that 61.5% of patients had at least one local side effect (Fig 2). The frequencies of side effects for BDP vs BUD are shown in Figure 2. 7 There was no placebo CHEST / 130 / 1/ JULY, 2006 SUPPLEMENT 43S

4 Figure 2. Frequency of local side effects in asthmatic children for all patients and for those receiving either BDP or BUD. Dysphonia, hoarseness, cough, and thirst were obtained by patient questioning and oral candidiasis was defined as a clinical observation of thrush. Adapted from Dubus et al. 7 *p BDP vs BUD. control group. Cough during inhalation was significantly higher with BDP than with BUD; otherwise, the tolerability of the two therapies was similar. 7 Dysphonia was the only side effect that appeared to be dose related, with a reduced frequency at low doses of BUD (p 0.05). Perioral dermatitis and tongue hypertrophy were also observed in 2.9% and 0.1% of patients, respectively. The investigators 7 also studied the effect of device on local side effects. The main finding was that use of a spacer device doubled the incidence of cough during inhalation, and this was independent of the ICS used. These results were confirmed in a follow-up study 4 in 219 patients, which noted cough on inhalation in 53.7% of patients using a spacer device; this was not linked to asthma severity, ICS, propellant or dispersant, or type of spacer, but was linked to therapy duration and use of long-acting 2 -agonists. Dysphonia was more frequent with a pressurized metered-dose inhaler (pmdi) plus a spacer or a nebulizer vs the other devices. 7 Perioral dermatitis was seen only in patients who used a spacer device with a facemask or a nebulizer with or without a facemask/mouthpiece. 7 Inhaler Device and Local Side Effects Inhaler device can also influence the occurrence of local side effects, mainly through determining the relative amount of drug deposited in the lungs vs the oropharynx. Ideally, a device should maximize the proportion of drug that reaches the lung; higher lung deposition reduces the required dose, and lower oropharyngeal deposition reduces the potential for oropharyngeal side effects. 26 Two types of inhaler device are used by the majority of asthma patients. In a pmdi, the drug is dissolved or suspended in a propellant under pressure, and when activated releases a predetermined dose. 27 A pmdi can be used with or without a spacer and can be manually or breath actuated. Use of a spacer device may improve lung deposition and reduce oropharyngeal deposition for patients with poor inhaler technique. 28 The choice of propellant greatly influences drug deposition. Chlorofluorocarbon (CFC) propellants used to be ubiquitous, but concern over their effect on the depletion of ozone in the upper atmosphere has led to their replacement with hydrofluoroalkane (HFA). 27 The use of HFA has had some additional benefits. Because particle sizes of 5 m diameter will reach the lower airways when larger particles are deposited in the oropharynx, 29 and because smaller particle sizes can be achieved with HFA, the use of HFA will likely lead to greater lung deposition, allowing lower doses, and lower oropharyngeal deposition. 30 With CFC-based pmdi devices, lung deposition was approximately 10 to 20% depending on the exact device and method of measurement. 26 In contrast, newer HFA-based inhalers are achieving levels of lung deposition 50%. 31 Dry powder inhalers (DPIs) do not require propellants and use inspiratory efforts to disperse the drug and deliver it to the lungs. 27 Lung deposition with these devices is approximately 15 to 40%, with considerable interdevice variability. 30 Thus, modern pmdi devices that use HFA propellants are at least as good as DPI devices in achieving high lung deposition. It is important to realize that a patient who is having local side effects using one drug/device combination may tolerate the same drug very differently using a different device. There is a great deal of variability in the reported local side effects of ICS in general and for specific agents. Much of this is due to how side effects are defined and assessed. As many studies compared active agents, without a placebo group, the accuracy of the risk estimation for side effects is often unknown. Nevertheless, the weight of evidence suggests that the risk of local side effects may be higher with FP than with BDP. Systemic Side Effects With ICS Therapy Systemic Availability of ICS ICS absorption into the systemic circulation occurs either through the lungs or by swallowing drug that is not inhaled but deposited at the back of the throat. 32 Nevertheless, other factors need to be considered and these are discussed below. 44S Decreasing the Global Burden of Asthma

5 The contribution of GI absorption to systemic ICS exposure is minimal compared with that of absorption through the lungs. 32 ICS that are swallowed and absorbed in the gut will undergo hepatic first-pass metabolism, greatly reducing the amount of circulating drug. 33 The degree of hepatic first-pass metabolism differs between ICS: FP and MF, 99%; BUD, 90%; TAA, 80 to 90%; and BDP, 60 to 70%. 33 Theoretically, agents that are inactivated by hepatic first-pass metabolism should be safer. However, highly lipophilic drugs, such as FP and MF, will be taken up more readily into tissues than drugs that are less lipophilic, such as TAA and BUD. Because more extensive tissue storage of ICS in an active form will result in a longer clearance time from the body, this not only may increase the duration of therapeutic effect but it also may increase the potential for increased systemic side effects should active drug continue to be released back into the circulation. 33 There is another potential reason why there is an increased risk of systemic side effects with MF. In contrast to other ICS, MF generates an active metabolite (6 -OH MF) in the liver and an active degradation product (9,11-epoxy MF) in the lung and plasma. 34 Even though MF itself has a low systemic bioavailability, these active metabolites will contribute to the overall potential for MF therapy to cause systemic side effects. 34 It has been shown that MF does cause significant overnight urinary cortisol suppression, a marker for hypothalamic-pituitaryadrenal axis suppression, to a similar extent as FP. 35 Most systemic ICS originates from direct absorption into the circulation through lower airway deposition. This route avoids hepatic first-pass metabolism. Drugs that are highly protein bound in the circulation will have a low potential for causing systemic side effects because only the free fraction is biologically active. The degree of protein binding is 71% for TAA, 80% for flunisolide (FLU), 88% for BUD, 90% for FP, and 99% for ciclesonide (CIC). 36,37 Protein binding for BDP is 87%, but no data are available for its active metabolite, 17 beclomethasone monopropionate. 36 Factors that increase ICS airway delivery may improve efficacy but may also increase the risk of systemic side effects. 32 For example, patients with mild disease have less airway obstruction than patients with more severe disease, increasing the deposition of ICS into the lower airways, possibly increasing the risk of side effects for the same ICS dose. 32 For example, administration of inhaled FP (1,000 g) to normal, healthy subjects resulted in higher peak plasma concentrations and greater total drug systemic exposure than for asthma patients. 38 Systemic availability of FP was also lower in asthma patients than in healthy control subjects, with a mild correlation to lung function as measured by FEV 1 (r 0.47, p 0.02). 38 Modern delivery systems, such as HFA-based pmdi inhalers, enhance drug targeting to the lungs. 30 Thus, lower ICS doses can be used, such that the clinical response is maintained but systemic exposure reduced. 39 For example, conversion from CFC to HFA as a propellant moved the doseresponse curve for drugs delivered using the HFA device toward the left, so lower doses are required to achieve the same therapeutic effect. 40,41 Conversely, a 1:1 substitution of the CFC to the more recent HFA formulations may result in greater systemic exposure and a higher potential for side effects. 32,41 Therefore, recommended doses of HFA devices are lower than older CFC-containing formulations. 5 Large-volume spacers have also been recommended as a means of improving lung deposition, allowing dose reduction and minimization of ICS systemic bioavailability in adults and children. 28 The Asthma Clinical Research Network conducted a randomized study 42 to investigate the systemic bioavailability of different ICS and devices using overnight urinary cortisol suppression to assess dose response. The study took place over 6 weeks, with the first week consisting of a placebo run-in phase. Five ICS compounds were evaluated: FP (as a CFC-pMDI formulation and a DPI formulation); BUD (DPI formulation); BDP (CFC-pMDI formulation); FLU (CFC-pMDI formulation); and TAA (CFC-pMDI formulation). The results were used to relate the ICS dose and delivery mechanism to an estimated effect on cortisol suppression (ie, their systemic availability) and determine equisuppressive doses. Table 1 shows the estimated doses of the different formulations that would cause a 10% suppression of endogenous cortisol production. 42 This study showed that FP delivered using a CFC-pMDI with a spacer required the lowest labeled dose to suppress cortisol production by 10%; and FLU, also delivered using a CFC-pMDI plus spacer, required the highest dose to obtain the same effect (Table 1). Table 1 Estimated Doses of ICS Formulations That Would Produce a 10% Suppression in Cortisol* Formulation Labeled Dose, g (95% CI) Emitted Dose, g (95% CI) FLU CFC-pMDI plus spacer 936 (484 1,387) 295 ( ) TAA CFC-pMDI plus spacer 787 ( ) 309 ( ) BDP CFC-pMDI plus spacer 548 ( ) 168 (71 266) FP DPI 445 (0 918) 440 (0 907) BUD DPI 268 ( ) 164 (94 235) FP CFC-pMDI plus spacer 111 (67 154) 68 (41 95) *Adapted From Martin et al CHEST / 130 / 1/ JULY, 2006 SUPPLEMENT 45S

6 This study 42 also showed that it is possible to conduct pharmacokinetic studies that allow comparison of hypothalamic-pituitary-adrenal axis suppression between different drug/device combinations. Such studies provide information regarding the potential for different ICS compounds, doses and formulations to cause systemic side effects. Risk of Systemic Side Effects While safety data have been reported for many clinical trials, there are few studies that have been adequately powered, or have long enough follow-up periods, to assess long-term systemic side effects with ICS. A systematic review 6 conducted in collaboration between the American College of Chest Physicians, the American Academy of Allergy, Asthma, and Immunology, and the American College of Allergy, Asthma, and Immunology examined the evidence for potential systemic complications of ICS therapy for asthma. Evidence published up to the end of the year 2000 was considered. The results are summarized in Table 2. In brief, there was relatively good evidence for the effect of ICS on skin thinning and bruising, with a dose-response relationship identified. In older adults, ICS appeared to reduce bone mineral density after long-term, high-dose therapy and increased the risk of cataracts and glaucoma, although the evidence was not conclusive. Two studies 43,44 investigating ICS effects on bone mineral density and fractures were not included in the systematic review. A study 43 from 1998 examined the effect of ICS on bone mineral density in 34 female and 19 male patients with persistent asthma who had received high-dose ICS (inhaled BDP or BUD at doses 1,500 g/d) for at least 12 months, Table 2 Conclusions of an Expert Panel Systematic Review of Side Effects With ICS Therapy* Evidence Grade Effect on: Conclusion A Bone mineral density, children ICS use is not associated with a reduction in bone density in children with asthma. C Bone mineral density, adults Adult asthma patients generally do not sustain a significant reduction in bone mineral density in response to ICS treatment, although the effect may become clinically important in patients receiving high-dose ICS for many years. C Cataracts The risk of subcapsular and nuclear cataracts associated with ICS use is negligible in young asthma patients, however, it may be elevated in older patients. F Cataracts There is insufficient information regarding differences in the risk of cataract formation between various ICS formulations. F Cataracts The dose-effect relationship between ICS use and cataract formation is poorly understood. F Glaucoma The risk of glaucoma associated with ICS use is likely to be small; however, further study is warranted. F Glaucoma There is insufficient information regarding differences in the risk of glaucoma between various ICS formulations. F Glaucoma There is an apparent, although poorly studied, dose-effect relationship between ICS use and glaucoma. A Growth Therapy with ICS is associated with a decrease in short-term growth rates in children, but the overall effect is small and may not be sustained with long-term therapy. C Growth The adult height attained by asthmatic children treated with ICS is not different from that of nonasthmatic adults. C Growth There is insufficient information on the difference between steroid formulations to derive definitive conclusions regarding their effects on growth. B Skin The risk of skin thinning and easy bruising is elevated in patients receiving ICS. Dose, duration of use, and patient gender are important variables affecting overall risk. F Skin There is insufficient information regarding differences in the risk of skin thinning/bruising between various ICS formulations. B Skin There is an apparent dose-effect relationship between ICS use and skin thinning/bruising. *Adapted from Leone et al. 6 Evidence grade A: there are sufficient data for evaluating the relationship between drug and complication. Conclusions are derived from at least two consistent, well-done, randomized, blinded clinical trials, and may be further supported by observational studies. Evidence grade B: there are sufficient data for evaluating the relationship between drug and complication. Conclusions are derived from more than one well-done observational study, but have not been confirmed by prospective, randomized, blinded clinical trials. Evidence grade C: there are sufficient data for evaluating the relationship between drug and complication. Conclusions are supported by the preponderance of evidence. However, high-quality conflicting data are available and imply that caution be applied. Evidence grade D: there are insufficient or conflicting data evaluating the relationship between drug and complication. An association may exist and may be supported by the majority of evidence. However, significant conflicting evidence warrants further attention. Evidence grade E: failed evidence review. There are insufficient data for evaluating the relationship between the drug and complication, studies are of poor design, and evidence is anecdotal or simply not available. Evidence-based conclusions cannot be derived. 46S Decreasing the Global Burden of Asthma

7 with or without a history of maintenance therapy with oral corticosteroids ( 1 month). The investigators 43 found that lumbar spine and proximal femur bone mineral density was 1 SD lower than normal in men and women receiving oral corticosteroids or high-dose ICS, equal to a doubling of the risk of fracture at these sites. In women, prior exposure to oral corticosteroids was also associated with lower lumbar spine and proximal femur bone mineral density than normal, while men were more sensitive to the side effects of ICS on bone mineral density at the lumbar spine and the Ward triangle. 43 All patients had evidence of suppression of both endogenous cortisol and adrenal androgen production, indicating hypothalamic-pituitary-adrenal axis suppression; this study 43 therefore supports an effect of high-dose ICS on bone mineral density. A retrospective cohort study 44 conducted in the United Kingdom after the systematic review 43 described above was compiled investigated the fracture risk with ICS. Patients who were using systemic corticosteroids were excluded from this study, leaving 170,818 ICS users, 108,786 bronchodilator users, and 170,818 control patients. During ICS therapy, there was an increased relative risk (RR) for nonvertebral fractures (RR, 1.15; 95% confidence interval [CI], 1.10 to 1.20), hip (RR, 1.22; 95% CI, 1.04 to 1.43), and vertebral fractures (RR, 1.5; 95% CI, 1.22 to 1.85). 44 The RR of fractures was similar for BUD, FP, and BDP. However, there were no differences in fracture risk between the ICS group and the bronchodilator groups, and the authors 44 suggested that the excess risk of fractures with ICS may be related to the underlying respiratory disease. Further prospective data are required on fracture risk with ICS therapy in order to clarify these findings. Oral corticosteroids are a known risk factor for the development of subcapsular cataracts, with risk influenced by daily cumulative dose, age, and ethnic origin. 45 The systematic review 6 described above concluded that the risk of cataracts due to ICS was small and may only be relevant in elderly patients. Two studies 46,47 not included in the systematic review generally support these findings. A study 46 from 1993 found that the prevalence of subcapsular cataracts in 48 patients treated with long-term BUD or BDP (750 to 1,500 g/d) was 27%. However, the development of cataracts was correlated to prednisone but not ICS use. A study 47 published in 2001, after the systematic review was compiled, suggested that the risk of cataracts with ICS may be related to age. An analysis of 103,289 subjects exposed to ICS vs 98,527 subjects in a control cohort found slightly higher incidence rates for cataracts in the ICS group compared with the nonexposed cohort (RR, 1.3; 95%, CI 1.1 to 1.5) after adjusting for age and gender. 47 However, a relationship between heavy use of ICS and cataract risk that was most pronounced in subjects 70 years old was also seen in subjects aged 40 to 49 years, but was absent in subjects aged 40 years. 47 The evidence for an effect of ICS on glaucoma was poor in the systematic review. 6 However, a more recent study 48 of 3,654 patients found a strong association between ICS use and the presence of either glaucoma or elevated intraocular pressure (odds ratio, 2.6; 95% CI, 1.2 to 5.8), but only in those patients with a family history of glaucoma. The risk increased with higher ICS doses (odds ratio, 6.3; 95% CI, 1.0 to 38.6, for more than four puffs per day). These findings were not explained by concurrent use of oral or ocular corticosteroids. 48 Systemic Side Effects in Children ICS safety in children was reviewed in 2002 by the NAEPP guidelines update 5 on selected topics. The report examined four outcomes: vertical growth, bone mineral density, ocular toxicity (including posterior subcapsular cataract and glaucoma), and suppression of hypothalamic-pituitary-adrenal axis function. The conclusions of this review are outlined in Table 3. 5 There was evidence to support a reduction in linear growth and suppression of the hypothalamicpituitary-adrenal axis with ICS. Although ICS have the potential to decrease growth velocity, there was no evidence that ICS therapy affected final adult height. However, the authors 5 drew attention to the need for further study regarding the long-term effects of ICS on bone mineral density and cataract formation, and whether the effects of ICS on growth velocity were more pronounced for certain developmental periods. The only other systemic side effect with ICS mentioned in the NAEPP 1997 guidelines was disseminated varicella infection. 1 While oral corticosteroid use, with or without immunosuppression, has been associated with a high risk of severe varicella infection compared with case-matched control subjects, 49 no causal relationship has been shown with ICS, 1 despite sporadic case reports of severe varicella infections in patients receiving ICS. 50 Control and Monitoring of Side Effects Local Side Effects The 1997 NAEPP guidelines 1 suggested the following clinical interventions to mitigate the risk of, or treat, local side effects: Oral candidiasis (thrush): use a spacer/holding chamber, rinse mouth with water after inhalation, and administer ICS less frequently (twice daily vs CHEST / 130 / 1/ JULY, 2006 SUPPLEMENT 47S

8 Table 3 Systemic Side Effects With ICS Therapy in Children* Evidence Grade Effect on: Conclusion A, B, C Growth Low-to-medium doses of ICS may have the potential to decrease growth velocity, although the effects are small, nonprogressive, and may be reversible. A Bone mineral density Low-to-medium doses of ICS appear to have no serious adverse effects on bone mineral density. A, C Cataracts/ glaucoma Low-to-medium doses of ICS have no significant effects on the incidence of subcapsular cataracts or glaucoma. A, C Hypothalamic-pituitary-adrenal axis function On average, children may experience only clinically insignificant, if any, effects on the hypothalamic-pituitary-adrenal axis. Rare individuals, however, may be susceptible to ICS effects on hypothalamic-pituitary-adrenal axis even at conventional doses. *Adapted from NAEPP Guidelines Update on Selected Topics Evidence grade A: randomized controlled trials, rich body of data. Evidence is from end points of well-designed randomized controlled trials that provide a consistent pattern of findings in the population for which the recommendation is made. Category A requires substantial numbers of studies involving substantial numbers of participants. Evidence grade B: randomized controlled trials and limited body of data. Evidence is from end points of intervention studies that include only a limited number of patients, post hoc or subgroup analysis of randomized controlled trials, or metaanalysis of randomized controlled trials. In general, category B pertains when few randomized controlled trials exist, they are small in size, they were undertaken in a population that differs from the target population of the recommendation, or the results are somewhat inconsistent. Evidence grade C: nonrandomized trials and observational studies. Evidence is from outcomes of uncontrolled or nonrandomized trials or from observational studies. Evidence grade D: panel consensus judgment. This category is used only in cases in which the provision of some guidance was deemed valuable but the clinical literature addressing the subject was insufficient to justify placement in one of the other categories. The Panel consensus is based on clinical experience or knowledge that does not meet the criteria for categories A through C. four times daily). Topical or oral antifungal agents should be used to treat active infections. Dysphonia: use a spacer/holding chamber, temporarily reduce dosage, or rest for vocal stress. Reflex cough and bronchospasm: use a slower inspiration rate and/or a spacer/holding chamber or pretreat with an inhaled 2 -agonist. These recommendations were based on the evidence available at the time. However, subsequent investigation of some of these interventions has provided contrary results. For example, in a study 7 in children, mouth rinsing or spacer use had no protective effect regarding the development of oral candidiasis. In a study 51 designed to assess the effect of gargling after ICS inhalation, at least in a subgroup of asthmatics using steroid inhalers, gargling with water, or even weak concentrations of amphotericin B did not prevent colonization of the throat with Candida albicans. However, gargling with amphotericin B at concentrations 100 times dilution did prevent clinically detectable oral candidiasis. 51 Moreover, two studies 4,7 in children showed that dysphonia and cough were more frequent in patients using a spacer device. It is unclear whether patients in these studies were coughing because they were using a spacer device or whether, in line with the guidelines, patients with cough on inhalation were more likely to have been administered a spacer to attempt to reduce the occurrence of this side effect. However, in adults, the use of a large-volume spacing device did not appear to protect against dysphonia or cough. 21 Systemic Side Effects The only specific recommendation for monitoring systemic side effects made in the NAEPP 1997 guidelines 1 was to monitor growth in children. However, based on the evidence available at the time, the guidelines 1 recommended the following measures for minimizing potential systemic side effects with ICS: Use a spacer device and rinse the mouth after inhalation. Selroos and Halme 52 demonstrated that systemic absorption of ICS was reduced by using a spacing device with a metered-dose inhaler after using a DPI. Figure 3. Physicians working in managed-care organizations reporting at least moderate concern regarding ICS side effects. Adapted from Finkelstein et al S Decreasing the Global Burden of Asthma

9 Use the lowest possible dose of ICS to maintain control. In children, step down ICS dose whenever possible. Add additional therapies (long-acting 2 -agonist) before increasing the ICS dose. In postmenopausal women, consider calcium supplements (1,000 to 1,500 mg/d) and vitamin D (400 IU/d). Estrogen replacement therapy, when appropriate, may be considered for patients receiving ICS doses 1,000 g/d. This recommendation is no longer up to date (see next paragraph). Varicella vaccination was not included in the recommendations for patients receiving ICS. Since these guidelines 1 were published, the recommendations have changed for postmenopausal women. While it is reasonable to recommend that women consume the recommended daily amounts of vitamin D and calcium in diet and supplements, the literature suggests that calcium and vitamin D supplementation by themselves are insufficient to prevent fractures in postmenopausal women. 53,54 Also, publication of the Women s Health Initiative Estrogen Plus Progestin Trial 55 on the risk/benefit profile of hormone replacement therapy has resulted in this no longer being indicated for routine use in postmenopausal women as a viable intervention for primary prevention of chronic diseases. Optimization of other steroid-sparing strategies has also been suggested, such as control of smoke and allergen exposure, influenza vaccination, and treatment of Figure 4. Clinical experience of asthma specialists regarding the frequency of side effects with ICS. ACTH adrenocorticotropic hormone. Adapted from Storms and Theen CHEST / 130 / 1/ JULY, 2006 SUPPLEMENT 49S

10 Figure 5. Top: Side effects of ICS of most concern to the asthma experts participating in this meeting (n 25): local side effects (black bars) and systemic side effects (open bars). Bottom: Asthma experts estimation of the frequency of ICS side effects seen in their practices. 50S Decreasing the Global Burden of Asthma

11 rhinitis, sinusitis, and gastroesophageal reflux disease when present. 56 In patients with osteoporosis, additional therapy with agents that have been shown to decrease the risk of fractures such as antiresorptive drugs is indicated. Physician Perception of Side Effects With ICS Therapy A survey 57 of 429 US family physicians and pediatricians in managed-care organizations was conducted by the Pediatric Asthma Care Patient Outcomes Research Team. This survey focused on physicians concerns and perceptions. Although 26% of responders thought ICS were very safe and 66% thought they were safe, 47% were at least moderately concerned regarding one or more ICS side effects (Fig 3). 57 Their greatest concern was regarding linear growth retardation in children. This survey predated the Food and Drug Administration requirement to include a warning on ICS labeling regarding linear growth retardation in children. In a survey 58 of 213 asthma specialists, 80% of whom were allergists/immunologists and 20% were pulmonologists, the aim was to determine the type and frequency of side effects due to ICS seen in their patients (Fig 4). Only 1% of physicians reported that they saw short stature in children either occasionally or frequently, and only 15% reported seeing it rarely. 58 The only area of agreement between these two studies was for oral thrush/oropharyngeal symptoms. There seems to be a disconnect between the level of concern regarding side effects with ICS and the actual frequency of these side effects noted in practice. However, it is likely that the family physicians were more concerned regarding the seriousness of potential side effects, rather than their frequency. Participant Feedback and Discussion During the workshop following this presentation, participants were asked a number of questions that they could respond to anonymously using an electronic interactive keypad system. Responses to most of these questions (listed below) are shown in Figure 5. On a scale of 1 to 6, how would you rate ICS safety overall? Which local adverse event is of most concern in your practice? How often do you see: Oral candidiasis? Esophageal candidiasis? Dysphonia/hoarseness? Pharyngitis? Cough? Which systemic event is of most concern in your practice? How often do you see: Issues with bone mineral density? ICS-related glaucoma or cataracts? Skin bruising? Linear growth issues in children? Adrenal suppression? How often do you monitor for (1) systemic or (2) local adverse events? When asked to rate the overall safety of ICS on a scale of 1 (very safe) to 6 (dangerous), 25% of participants in this meeting rated ICS as very safe, most (40%) chose 2 on the scale, and 35% chose 3 or 4. Participants believed that local side effects were most likely to lead to discontinuation of therapy. 27 Approximately two thirds of the participants monitored for local side effects at each visit; the remainder relied on the patient to alert them to any problems. Most of the group (50%) investigated systemic side effects only in the event of a patient indicating that there was a problem. The remainder monitored at regular periods: every 6 months (21%), every quarter (4%), or every visit (25%). Considerable reservations remain for parents and many pediatricians regarding the effect of ICS on linear growth in children: cataracts may be more common with ICS in older patients; bone density is a risk in postmenopausal women and elderly men; patients with a family history of glaucoma may be more at risk of this side effect with ICS; and skin bruising occurs even at moderate ICS doses. Conclusion When reading the NAEPP 1997 guidelines, 1 understanding the potential side effects of ICS therapy and their control and monitoring seems relatively clear and straightforward. In this context, the concerns of many physicians (and patients) may seem misplaced. However, on closer examination of the clinical trial data used to develop the guidelines, as well as subsequent studies, we see that there are many unknowns and gaps in our knowledge, leaving space for doubt and confusion. We know that local side effects such as oral candidiasis, pharyngitis, and dysphonia/cough can be unpleasant and lead to poor therapy adherence, even though they are not serious. The fear of systemic side effects, such as reduced bone mineral density, skin CHEST / 130 / 1/ JULY, 2006 SUPPLEMENT 51S

12 bruising, glaucoma, cataracts, and growth retardation in children, may appear to be out of proportion to the risks. However, given the seriousness of these potential side effects and the lack of clear data, these fears are understandable. We know that ICS are a highly effective therapy for control of asthma symptoms, and we must now concentrate on furthering our understanding of the risks of therapy. Different perceptions of the risks of ICS therapy will result in different balance points for the risk/benefit decision that physicians and patients must make on initiating ICS therapy. There is a need for an ICS formulation that will allow high-dose therapy for extended periods, with a confirmed dose response and with a decreased potential for side effects (ie, a broader therapeutic window). The introduction of new agents with improved safety profiles will also reassure physicians and patients as to the benefits of ICS therapy. References 1 National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, 1997; publication No Gilberg K, Laouri M, Wade S, et al. Analysis of medication use patterns: apparent overuse of antibiotics and underuse of prescription drugs for asthma, depression, and CHF. J Manag Care Pharm 2003; 9: Weltman JK. The use of inhaled corticosteroids in asthma. Allergy Asthma Proc 1999; 20: Dubus JC, Mely L, Huiart L, et al. Cough after inhalation of corticosteroids delivered from spacer devices in children with asthma. Fundam Clin Pharmacol 2003; 17: National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma; update on selected topics J Allergy Clin Immunol 2002; 110(5 Suppl):S141 S219 6 Leone FT, Fish JE, Szefler SJ, et al. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma and Immunology, and American College of Allergy, Asthma and Immunology. Chest 2003; 124: Dubus JC, Marguet C, Deschildre A, et al. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy 2001; 56: Adams N, Bestall J, Jones PW. Inhaled fluticasone propionate for chronic asthma. Cochrane Database Syst Rev 2001; 3:CD Adams N, Bestall J, Jones PW. Budesonide for chronic asthma in children and adults. Cochrane Database Syst Rev 2001; 4:CD Adams N, Bestall JM, Jones PW. Inhaled fluticasone at different doses for chronic asthma. Cochrane Database Syst Rev 2002; 1:CD Adams N, Bestall J, Lasserson T, et al. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma. Cochrane Database Syst Rev 2004; 2:CD Engelstätter R, Banerji D, Steinijans VW, et al. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide: results from a pooled analysis [abstract]. Am J Respir Crit Care Med 2004; 169:A92 13 Bousquet J, D Urzo A, Hebert J, et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000; 16: Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 2001; 61: Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust 2003; 178: Kanda N, Yasuba H, Takahashi T, et al. Prevalence of esophageal candidiasis among patients treated with inhaled fluticasone propionate. Am J Gastroenterol 2003; 98: Shuto H, Nagata M, Terashi Y, et al. Esophageal candidiasis as complication of inhaled steroid therapy. Arerugi 2003; 52: (in Japanese) 18 Toogood JH, Jennings B, Greenway RW, et al. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J Allergy Clin Immunol 1980; 65: Toogood JH, White FA, Baskerville JC, et al. Comparison of antiasthmatic, oropharyngeal, and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhaler. J Allergy Clin Immunol 1997; 99: Bernstein DI, Berkowitz RB, Chervinsky P, et al. Doseranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999; 93: Williamson IJ, Matusiewicz SP, Brown PH, et al. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J 1995; 8: Baraniuk J, Murray JJ, Nathan RA, et al. Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. Chest 1999; 116: McGavin JK, Goa KL, Jarvis B. Inhaled budesonide/formoterol combination. Drugs 2001; 61: Spencer CM, Jarvis B. Salmeterol/fluticasone propionate combination. Drugs 1999; 57: Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 g)/salmeterol (50 g) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124: Pauwels R, Newman S, Borgstrom L. Airway deposition and airway effects of antiasthma drugs delivered from metereddose inhalers. Eur Respir J 1997; 10: Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004; 126: Newman SP. Spacer devices for metered dose inhalers. Clin Pharmacokinet 2004; 43: Stahlhofen W, Gebhart J, Heyder J Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. Am Ind Hyg Assoc J 1980; 41:385a 398a 30 Anderson PJ. Delivery options and devices for aerosolized therapeutics. Chest 2001; 120(Suppl):89S 93S 31 Newman S, Salmon A, Nave R, et al. High lung deposition of 99prTc labelled ciclesonide administered via HFA-MDI to asthma patients [abstract]. Eur Respir J 2004; 24(suppl 48):583S 32 Skoner DP. Balancing safety and efficacy in pediatric asthma management. Pediatrics 2002; 109(suppl 2): Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf 2000; 23: Valotis A, Hogger P. Significant receptor affinities of metab- 52S Decreasing the Global Burden of Asthma

13 olites and a degradation product of mometasone furoate. Respir Res 2004; 5:7 35 Fardon TC, Lee DK, Haggart K, et al. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004; 170: Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91(Suppl A): Rohatagi S, Derendorf H, Zech K, et al. PK/PD of inhaled corticosteroids: the risk/benefit of inhaled ciclesonide [abstract]. J Allergy Clin Immunol 2003; 111:S Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356: Newman SP. Deposition and effects of inhaled corticosteroids. Clin Pharmacokinet 2003; 42: Fowler SJ, Orr LC, Sims EJ, et al. Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate. Chest 2002; 122: Lipworth BJ, Jackson CM. Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate. Br J Clin Pharmacol 1999; 48: Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002; 165: Ebeling PR, Erbas B, Hopper JL, et al. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J Bone Miner Res 1998; 13: van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001; 16: Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159: Toogood JH, Markov AE, Baskerville J, et al. Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment of asthma. J Allergy Clin Immunol 1993; 91: Jick SS, Vasilakis-Scaramozza C, Maier WC. The risk of cataract among users of inhaled steroids. Epidemiology 2001; 12: Mitchell P, Cumming RG, Mackey DA. Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology 1999; 106: Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics 1993; 92: Choong K, Zwaigenbaum L, Onyett H. Severe varicella after low dose inhaled corticosteroids. Pediatr Infect Dis J 1995; 14: Fukushima C, Shimoda T, Kawano T, et al. Effects of amphotericin B gargles on oral colonization of Candida albicans in asthmatic patients on steroid inhalation therapy. Respiration 2001; 68: Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax 1991; 46: Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: Finkelstein JS. Calcium plus vitamin D for postmenopausal women: bone appétit [editorial]? N Engl J Med 2006; 354: (correction: 2006; 354:1102) 55 Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women s Health Initiative randomized controlled trial. JAMA 2002; 288: Skoner DP. Growth effects of asthma and asthma therapy. Curr Opin Pulm Med 2002; 8: Finkelstein JA, Lozano P, Shulruff R, et al. Self-reported physician practices for children with asthma: are national guidelines followed? Pediatrics 2000; 106(4 Suppl): Storms WW, Theen C. Clinical adverse effects of inhaled corticosteroids: results of a questionnaire survey of asthma specialists. Ann Allergy Asthma Immunol 1998; 80: CHEST / 130 / 1/ JULY, 2006 SUPPLEMENT 53S

Asthma POEMs. Patient Orientated Evidence that Matters

Asthma POEMs. Patient Orientated Evidence that Matters ASTHMA POEMs Asthma POEMs Patient Orientated Evidence that Matters Developed by the Best Practice Advocacy Centre Level 8, 10 George Street PO Box 6032 Dunedin Phone 03 4775418 Fax 03 4772622 Acknowledgement

More information

Inhaled and Oral Corticosteroids

Inhaled and Oral Corticosteroids Inhaled and Oral Corticosteroids Corticosteroids (steroids) are medicines that are used to treat many chronic diseases. Corticosteroids are very good at reducing inflammation (swelling) and mucus production

More information

- Canine Chronic Bronchitis cannot be cured, but can be controlled

- Canine Chronic Bronchitis cannot be cured, but can be controlled MD-096A-0211 1 2 - The symptoms of asthma can mimic other diseases such as heartworm, pneumonia and congestive heart failure (Padrid, Use of Inhaled Medications to Treat Respiratory Diseases in Dogs and

More information

medicineupdate to find out more about this medicine

medicineupdate to find out more about this medicine medicineupdate Asking the right questions about new medicines Seretide for chronic obstructive pulmonary disease What this medicine is 1 What this medicine treats 2 Other medicines available for this condition

More information

The Annual Direct Care of Asthma

The Annual Direct Care of Asthma The Annual Direct Care of Asthma The annual direct health care cost of asthma in the United States is approximately $11.5 billion; indirect costs (e.g. lost productivity) add another $4.6 billion for a

More information

Personality influences the reporting of side effects of inhaled corticosteroids*

Personality influences the reporting of side effects of inhaled corticosteroids* Personality influences the reporting of side effects of inhaled corticosteroids* Dr. Juliet M. Foster Dept. Primary Care University Medical Center Groningen/ University of Aberdeen GRIAC (Groningen( Research

More information

Severe asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital

Severe asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital Severe asthma Definition, epidemiology and risk factors Mina Gaga Athens Chest Hospital Difficult asthma Defined as asthma, poorly controlled in terms of chronic symptoms, with episodic exacerbations,

More information

Prevention of Acute COPD exacerbations

Prevention of Acute COPD exacerbations December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal

More information

Pharmacology of the Respiratory Tract: COPD and Steroids

Pharmacology of the Respiratory Tract: COPD and Steroids Pharmacology of the Respiratory Tract: COPD and Steroids Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart

More information

events..strategies are needed to reduce the systemic effects of inhaled corticosteroids. (24)

events..strategies are needed to reduce the systemic effects of inhaled corticosteroids. (24) Inhaled and intranasal corticosteroids (ICS and INS) are guidelinerecommended, first-line therapies for asthma and allergic rhinitis, respectively.(1, 2) There are significant risks in adults and children

More information

COPD PROTOCOL CELLO. Leiden

COPD PROTOCOL CELLO. Leiden COPD PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives and medication of COPD. The Cello way of working can be viewed on

More information

MEDICATION INFORMATION: CONTROLLER MEDICATIONS

MEDICATION INFORMATION: CONTROLLER MEDICATIONS FRANK J. TWAROG, M.D., Ph.D. CURTIS T. MOODY, M.D. ADULT AND PEDIATRIC ASTHMA AND ALLERGIES Brookline Concord (617) 735-8750 (978) 369-3567 MEDICATION INFORMATION: CONTROLLER MEDICATIONS Asthma medications

More information

Asthma Intervention. An Independent Licensee of the Blue Cross and Blue Shield Association.

Asthma Intervention. An Independent Licensee of the Blue Cross and Blue Shield Association. Asthma Intervention 1. Primary disease education Member will have an increased understanding of asthma and the classification by severity, the risks and the complications. Define asthma Explain how lungs

More information

DATA SHEET. Fluticasone propionate Inhaler (CFC-Free) (50, 125 or 250 micrograms per actuation). Qualitative and quantitative composition

DATA SHEET. Fluticasone propionate Inhaler (CFC-Free) (50, 125 or 250 micrograms per actuation). Qualitative and quantitative composition DATA SHEET FLIXOTIDE Inhaler Fluticasone propionate Inhaler (CFC-Free) (50, 125 or 250 micrograms per actuation). Qualitative and quantitative composition FLIXOTIDE 50 Inhaler is a pressurised metered-dose

More information

MEDICATION GUIDE. SYMBICORT 80/4.5 (budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation Aerosol

MEDICATION GUIDE. SYMBICORT 80/4.5 (budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation Aerosol MEDICATION GUIDE SYMBICORT 80/4.5 (budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation Aerosol SYMBICORT 160/4.5 (budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation

More information

PRODUCT INFORMATION FLIXOTIDE JUNIOR INHALER, (CFC-FREE) INHALER, JUNIOR (CFC-FREE) INHALER, ACCUHALER AND JUNIOR ACCUHALER

PRODUCT INFORMATION FLIXOTIDE JUNIOR INHALER, (CFC-FREE) INHALER, JUNIOR (CFC-FREE) INHALER, ACCUHALER AND JUNIOR ACCUHALER PRODUCT INFORMATION FLIXOTIDE JUNIOR INHALER, (CFC-FREE) INHALER, JUNIOR (CFC-FREE) INHALER, ACCUHALER AND JUNIOR ACCUHALER AUSTRALIAN APPROVED NAME: Fluticasone propionate STRUCTURE: CHEMICAL NAME: S-Fluoromethyl

More information

Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma

Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma Important Complete asthma control needs to be achieved for at least 12 weeks before attempting

More information

Medication Guide DULERA [dew-lair-ah] 100 mcg/5 mcg DULERA 200 mcg/5 mcg

Medication Guide DULERA [dew-lair-ah] 100 mcg/5 mcg DULERA 200 mcg/5 mcg Medication Guide DULERA [dew-lair-ah] 100 mcg/5 mcg (mometasone furoate 100 mcg and formoterol fumarate dihydrate 5 mcg inhalation aerosol) DULERA 200 mcg/5 mcg (mometasone furoate 200 mcg and formoterol

More information

Drug therapy SHORT-ACTING BETA AGONISTS SHORT-ACTING ANTICHOLINERGICS LONG-ACTING BETA AGONISTS LONG-ACTING ANTICHOLINERGICS

Drug therapy SHORT-ACTING BETA AGONISTS SHORT-ACTING ANTICHOLINERGICS LONG-ACTING BETA AGONISTS LONG-ACTING ANTICHOLINERGICS Drug therapy 6 6.1 What is the role of bronchodilators in COPD? 52 SHORT-ACTING BETA AGONISTS 6.2 How do short-acting beta agonists work? 52 6.3 What are the indications for their use? 52 6.4 What is the

More information

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children 7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists

More information

The dose response characteristics of inhaled corticosteroids when used to treat asthma: An overview of Cochrane systematic reviews $

The dose response characteristics of inhaled corticosteroids when used to treat asthma: An overview of Cochrane systematic reviews $ Respiratory Medicine (2006) 100, 1297 1306 EVIDENCE-BASED REVIEW The dose response characteristics of inhaled corticosteroids when used to treat asthma: An overview of Cochrane systematic reviews $ N.P.

More information

Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD)

Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD) Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD) Patients with COPD take a wide variety of medicines to manage their symptoms these include: Inhaled Short Acting Bronchodilators

More information

Glucocorticoids, Inhaled Therapeutic Class Review (TCR) February 7, 2012

Glucocorticoids, Inhaled Therapeutic Class Review (TCR) February 7, 2012 Glucocorticoids, Inhaled Therapeutic Class Review (TCR) February 7, 2012 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying,

More information

Nursing 113. Pharmacology Principles

Nursing 113. Pharmacology Principles Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics

More information

Steroid treatment in cystic fibrosis

Steroid treatment in cystic fibrosis Steroid treatment in cystic fibrosis Factsheet March 2013 Steroid treatment in cystic fibrosis Introduction This factsheet contains information on steroid treatment in cystic fibrosis, including the different

More information

Glucocorticoids, Inhaled Therapeutic Class Review (TCR)

Glucocorticoids, Inhaled Therapeutic Class Review (TCR) Glucocorticoids, Inhaled Therapeutic Class Review (TCR) July 31, 2015 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying,

More information

Not All Clinical Trials Are Created Equal Understanding the Different Phases

Not All Clinical Trials Are Created Equal Understanding the Different Phases Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact

More information

4 Pharmacological management

4 Pharmacological management 4 Pharmacological management The aim of asthma management is control of the disease. Control of asthma is defined as: no daytime symptoms no night time awakening due to asthma no need for rescue medication

More information

Better Breathing with COPD

Better Breathing with COPD Better Breathing with COPD People with Chronic Obstructive Pulmonary Disease (COPD) often benefit from learning different breathing techniques. Pursed Lip Breathing Pursed Lip Breathing (PLB) can be very

More information

Cystic fibrosis and bone health

Cystic fibrosis and bone health Cystic fibrosis and bone health Factsheet March 2013 Cystic fibrosis and bone health Introduction As we get older our bones become thinner and weaker, and may become more susceptible to fracture. However

More information

"Respiratory Problems in Swimmers: How to keep Swimmers Afloat" and in the Pool!

Respiratory Problems in Swimmers: How to keep Swimmers Afloat and in the Pool! "Respiratory Problems in Swimmers: How to keep Swimmers Afloat" and in the Pool! Charles Siegel, MD Associate Clinical Professor University of Missouri @ Kansas City School of Medicine USA Swimming does

More information

YOU VE BEEN REFERRED TO AN ASTHMA SPECIALIST...

YOU VE BEEN REFERRED TO AN ASTHMA SPECIALIST... YOU VE BEEN REFERRED TO AN ASTHMA SPECIALIST... ...HERE S WHAT TO EXPECT You have been referred to an allergist because you have or may have asthma. The health professional who referred you wants you to

More information

Medicines Use Review Supporting Information for Asthma Patients

Medicines Use Review Supporting Information for Asthma Patients Medicines Use Review Supporting Information for Asthma Patients What is asthma? Asthma is a chronic inflammatory disorder of the airways. The inflammation causes an associated increase in airway hyper-responsiveness,

More information

Evaluating Steroid Inhalers Used to Treat: Asthma and Chronic Lung Disease. Comparing Effectiveness, Safety, and Price

Evaluating Steroid Inhalers Used to Treat: Asthma and Chronic Lung Disease. Comparing Effectiveness, Safety, and Price Evaluating Steroid Inhalers Used to Treat: Asthma and Chronic Lung Disease Comparing Effectiveness, Safety, and Price Our Recommendations Inhaled steroids are effective and safe medicines used to treat

More information

Standardizing the measurement of drug exposure

Standardizing the measurement of drug exposure Standardizing the measurement of drug exposure The ability to determine drug exposure in real-world clinical practice enables important insights for the optimal use of medicines and healthcare resources.

More information

C orticosteroids are highly effective therapy for persistent

C orticosteroids are highly effective therapy for persistent 457 ORIGINAL ARTICLE Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom G R G Todd, C L Acerini, R Ross-Russell, S Zahra, J T Warner, D McCance... Arch Dis Child 2002;87:457

More information

Guidance for Industry. Integration of Dose-Counting Mechanisms into MDI Drug Products

Guidance for Industry. Integration of Dose-Counting Mechanisms into MDI Drug Products Guidance for Industry Integration of Dose-Counting Mechanisms into MDI Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

Detach Patient's Instructions for Use from package insert and dispense with the product.

Detach Patient's Instructions for Use from package insert and dispense with the product. Attention Health Care Professional: Detach Patient's Instructions for Use from package insert and dispense with the product. PROVENTIL HFA (albuterol sulfate) Inhalation Aerosol FOR ORAL INHALATION ONLY

More information

Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Development of disability in COPD The decline in airway function may initially go unnoticed as people adapt their lives to avoid

More information

STAYING ASTHMA FREE. All you need to know about preventers. www.spacetobreathe.co.nz

STAYING ASTHMA FREE. All you need to know about preventers. www.spacetobreathe.co.nz STAYING ASTHMA FREE All you need to know about preventers www.spacetobreathe.co.nz HELPING YOUR CHILD BREATHE MORE EASILY GETTING TO KNOW THE PREVENTER What is a preventer? When do you use it? How do they

More information

Background information

Background information Background information Asthma Asthma is a complex disease affecting the lungs that can be managed but cannot be cured. 1 Asthma can be controlled well in most people most of the time, although some people

More information

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study

More information

A list of FDA-approved testosterone products can be found by searching for testosterone at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.

A list of FDA-approved testosterone products can be found by searching for testosterone at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke

More information

Selective IgA deficiency (slgad) hello@piduk.org 0800 987 8986 www.piduk.org

Selective IgA deficiency (slgad) hello@piduk.org 0800 987 8986 www.piduk.org Selective IgA deficiency (slgad) hello@piduk.org 0800 987 8986 www.piduk.org About this booklet This booklet provides information on selective IgA deficiency (sigad). It has been produced by the PID UK

More information

Seretide Diskus 50/100 Seretide Diskus 50/250 Seretide Diskus 50/500

Seretide Diskus 50/100 Seretide Diskus 50/250 Seretide Diskus 50/500 The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in November 2009 TITLE Salmeterol-Fluticasone Propionate (Salmeterol-FP) SCOPE Trade Name Salmeterol

More information

WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses

WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses 20 August 2009 Table of contents EXECUTIVE SUMMARY... i Other recommendations...iii 1. INTRODUCTION...

More information

A Guide for the Utilization of HIRA National Patient Samples. Logyoung Kim, Jee-Ae Kim, Sanghyun Kim. Health Insurance Review and Assessment Service

A Guide for the Utilization of HIRA National Patient Samples. Logyoung Kim, Jee-Ae Kim, Sanghyun Kim. Health Insurance Review and Assessment Service A Guide for the Utilization of HIRA National Patient Samples Logyoung Kim, Jee-Ae Kim, Sanghyun Kim (Health Insurance Review and Assessment Service) Jee-Ae Kim (Corresponding author) Senior Research Fellow

More information

SUMMARY OF THE RISK MANAGEMENT PLAN (by medicinal product)

SUMMARY OF THE RISK MANAGEMENT PLAN (by medicinal product) PART VI SUMMARY OF THE RISK MANAGEMENT PLAN (by medicinal product) Format and content of the summary of the RMP The summary of the RMP part VI contains information based on RMP modules SI, SVIII and RMP

More information

MOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines

MOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines MOH CLINICL PRCTICE GUIELINES 2/2008 Prescribing of Benzodiazepines College of Family Physicians, Singapore cademy of Medicine, Singapore Executive summary of recommendations etails of recommendations

More information

COPD and Asthma Differential Diagnosis

COPD and Asthma Differential Diagnosis COPD and Asthma Differential Diagnosis Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in America. Learning Objectives Use tools to effectively diagnose chronic obstructive

More information

Medication Guide DULERA [dew-lair-ah] 100 mcg/5 mcg DULERA 200 mcg/5 mcg

Medication Guide DULERA [dew-lair-ah] 100 mcg/5 mcg DULERA 200 mcg/5 mcg Medication Guide DULERA [dew-lair-ah] 100 mcg/5 mcg (mometasone furoate 100 mcg and formoterol fumarate dihydrate 5 mcg) Inhalation Aerosol DULERA 200 mcg/5 mcg (mometasone furoate 200 mcg and formoterol

More information

Drug Class Review on Inhaled Corticosteroids

Drug Class Review on Inhaled Corticosteroids Drug Class Review on Inhaled Corticosteroids Final Report January 2006 The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different

More information

Your health care provider may prescribe bronchodilators such as albuterol for emergency relief if an acute asthma attack occurs.

Your health care provider may prescribe bronchodilators such as albuterol for emergency relief if an acute asthma attack occurs. Patient Information ASMANEX TWISTHALER 220 mcg (mometasone furoate inhalation powder) ASMANEX TWISTHALER 110 mcg (mometasone furoate inhalation powder) FOR ORAL INHALATION ONLY Please read this leaflet

More information

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT

More information

FDA Briefing Document for Nonprescription Drugs Advisory Committee

FDA Briefing Document for Nonprescription Drugs Advisory Committee FDA Briefing Document for Nonprescription Drugs Advisory Committee Triamcinolone Acetonide Nasal Spray (Nasacort AQ) NDA 20468 Proposed Indication: Temporarily relieves these symptoms of hay fever or other

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

5. Treatment of Asthma in Children

5. Treatment of Asthma in Children Treatment of sthma in hildren 5. Treatment of sthma in hildren 5.1 Maintenance Treatment 5.1.1 rugs Inhaled Glucocorticoids. Persistent wheezing in children under the age of three can be controlled with

More information

9/16/2014. Anti-Immunoglobulin E (IgE) Omalizumab (Xolair ) Dosing Guidance

9/16/2014. Anti-Immunoglobulin E (IgE) Omalizumab (Xolair ) Dosing Guidance Disclosure Statement of Financial Interest New Therapies for Asthma Including Omalizumab and Anti-Cytokine Therapies Marsha Dangler, PharmD, BCACP Clinical Pharmacy Specialist James H. Quillen VA Medical

More information

Aging Well - Part V. Hormone Modulation -- Growth Hormone and Testosterone

Aging Well - Part V. Hormone Modulation -- Growth Hormone and Testosterone Aging Well - Part V Hormone Modulation -- Growth Hormone and Testosterone By: James L. Holly, MD (The Your Life Your Health article published in the December 4th Examiner was a first draft. It was sent

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testing_serum_vitamin_d_levels 9/2015 2/2016 2/2017 2/2016 Description of Procedure or Service Vitamin D,

More information

Differential effects of maintenance long-acting b-agonist and inhaled corticosteroid on asthma control and asthma exacerbations

Differential effects of maintenance long-acting b-agonist and inhaled corticosteroid on asthma control and asthma exacerbations Differential effects of maintenance long-acting b-agonist and inhaled corticosteroid on asthma control and asthma exacerbations Peter G. Gibson, MBBS(Hons), FRACP, a,b,d Heather Powell, MMedSci, a,d and

More information

The menopausal transition usually has three parts:

The menopausal transition usually has three parts: The menopausal transition usually has three parts: Perimenopause begins several years before a woman s last menstrual period, when the ovaries gradually produce less estrogen. In the last 1-2 years of

More information

SERETIDE Fluticasone propionate/salmeterol xinafoate Consumer Medicine Information

SERETIDE Fluticasone propionate/salmeterol xinafoate Consumer Medicine Information SERETIDE Fluticasone propionate/salmeterol xinafoate Consumer Medicine Information What is in this leaflet Please read this leaflet carefully before you start using Seretide. This leaflet answers some

More information

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 11/2014

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 11/2014 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARNUITY ELLIPTA safely and effectively. See full prescribing information for ARNUITY ELLIPTA. ARNUITY

More information

Common Mistakes with inhaler Technique

Common Mistakes with inhaler Technique Common Mistakes with inhaler Technique Inhaling medication into the lungs can be very effective - but frequently it is not. The most common reasons for patients not responding to treatment are:- Being

More information

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms Clinical Guideline Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,

More information

Information for Behavioral Health Providers in Primary Care. Asthma

Information for Behavioral Health Providers in Primary Care. Asthma What is Asthma? Information for Behavioral Health Providers in Primary Care Asthma Asthma (AZ-ma) is a chronic (long-term) lung disease that inflames and narrows the airways. Asthma causes recurring periods

More information

PLAN OF ACTION FOR. Physician Name Signature License Date

PLAN OF ACTION FOR. Physician Name Signature License Date PLAN OF ACTION FOR Patient s copy (patient s name) I Feel Well Lignes I feel short directrices of breath: I cough up sputum daily. No Yes, colour: I cough regularly. No Yes I Feel Worse I have changes

More information

COPD Intervention. Components:

COPD Intervention. Components: COPD Intervention 1. Primary disease education Member will have an increased understanding of chronic obstructive pulmonary disease, the causes, risks and complications. Explain COPD Explain how COPD is

More information

Patient Information Once Weekly FOSAMAX (FOSS-ah-max) (alendronate sodium) Tablets and Oral Solution

Patient Information Once Weekly FOSAMAX (FOSS-ah-max) (alendronate sodium) Tablets and Oral Solution Patient Information Once Weekly FOSAMAX (FOSS-ah-max) (alendronate sodium) Tablets and Oral Solution Read this information before you start taking FOSAMAX *. Also, read the leaflet each time you refill

More information

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms Clinical Guideline Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,

More information

Doncaster & Bassetlaw Medicines Formulary

Doncaster & Bassetlaw Medicines Formulary Doncaster & Bassetlaw Medicines Formulary Section 3.2: Corticosteroids Beclometasone 50, 100 and 250micrograms/dose Clickhaler Clenil Modulite (Beclometasone CFC free) 50, 100, and 250micrograms/dose MDI

More information

Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age

Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age Components of Severity Symptoms Intermittent 2 days/week Classification of Asthma Severity (0 4 years of age) Persistent

More information

An Overview of Asthma - Diagnosis and Treatment

An Overview of Asthma - Diagnosis and Treatment An Overview of Asthma - Diagnosis and Treatment Asthma is a common chronic disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness,

More information

How to use FENO-guided asthma control in routine clinical practice

How to use FENO-guided asthma control in routine clinical practice How to use FENO-guided asthma control in routine clinical practice Asthma is a chronic inflammatory disease of the airways. This has implications for the diagnosis, management and potential prevention

More information

Tests. Pulmonary Functions

Tests. Pulmonary Functions Pulmonary Functions Tests Static lung functions volumes Dynamic lung functions volume and velocity Dynamic Tests Velocity dependent on Airway resistance Resistance of lung tissue to change in shape Dynamic

More information

understanding the professional guidelines

understanding the professional guidelines SEVERE ASTHMA understanding the professional guidelines This guide includes information on what the European Respiratory Society (ERS) and the American Thoracic Society (ATS) have said about severe asthma.

More information

Systemic side effects of inhaled corticosteroids in patients with asthma

Systemic side effects of inhaled corticosteroids in patients with asthma Respiratory Medicine (2006) 100, 1307 1317 REVIEW Systemic side effects of inhaled corticosteroids in patients with asthma Ronald Dahl Department of Respiratory Diseases, Aarhus University Hospital, Norrebrogade,

More information

What You Need to Know for Better Bone Health

What You Need to Know for Better Bone Health What You Need to Know for Better Bone Health A quick lesson about bones: Why healthy bones matter The healthier your bones The more active you can be Bone health has a major effect on your quality of life

More information

The patient s response to therapy within the first hour in the Emergency Room is one of the most reliable ways to predict need for hospitalization.

The patient s response to therapy within the first hour in the Emergency Room is one of the most reliable ways to predict need for hospitalization. Emergency Room Asthma Management Algorithm The Emergency Room Asthma Management Algorithm is to be used for any patient seen in the Emergency Room with the diagnosis of asthma. (The initial history should

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

tips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden:

tips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden: tips Top International Publications Selection Insulin Pump Users Early detection of insulin deprivation in continuous subcutaneous insulin infusion-treated Patients with TD Population Study of Pediatric

More information

Factors Associated with Underutilization of Inhalation Corticosteroids. among Asthmatic Patients Attending Tikur Anbessa Specialized Hospital

Factors Associated with Underutilization of Inhalation Corticosteroids. among Asthmatic Patients Attending Tikur Anbessa Specialized Hospital Factors Associated with Underutilization of Inhalation Corticosteroids among Asthmatic Patients Attending Tikur Anbessa Specialized Hospital By: Yohanes Ayele (B. Pharm) A thesis submitted to the School

More information

Understanding and Controlling Asthma Attacks. Information for parents

Understanding and Controlling Asthma Attacks. Information for parents Understanding and Controlling Asthma Attacks Information for parents Your child was recently seen by a doctor for asthma. This guide will help you gain a better understanding about your child's recent

More information

ELEMENTS FOR A PUBLIC SUMMARY. Overview of disease epidemiology. Summary of treatment benefits

ELEMENTS FOR A PUBLIC SUMMARY. Overview of disease epidemiology. Summary of treatment benefits VI: 2 ELEMENTS FOR A PUBLIC SUMMARY Bicalutamide (CASODEX 1 ) is a hormonal therapy anticancer agent, used for the treatment of prostate cancer. Hormones are chemical messengers that help to control the

More information

Asthma and COPD Awareness

Asthma and COPD Awareness Asthma and COPD Awareness Molina Breathe with Ease sm and Chronic Obstructive Pulmonary Disease Molina Healthcare of Michigan Fall 2012 Importance of Controller Medicines Asthma is a disease that causes

More information

Summary of the risk management plan (RMP) for Ofev (nintedanib)

Summary of the risk management plan (RMP) for Ofev (nintedanib) EMA/738120/2014 Summary of the risk management plan (RMP) for Ofev (nintedanib) This is a summary of the risk management plan (RMP) for Ofev, which details the measures to be taken in order to ensure that

More information

For Mild to Moderate Plaque Psoriasis and Moderate to Severe Atopic Dermatitis

For Mild to Moderate Plaque Psoriasis and Moderate to Severe Atopic Dermatitis For Mild to Moderate Plaque Psoriasis and Moderate to Severe Atopic Dermatitis OLUX-E (clobetasol propionate) Foam, 0.05% Please see Important Safety Information on back page and accompanying Full Prescribing

More information

Role of Inhaled Corticosteroids

Role of Inhaled Corticosteroids CHAPTER 16 Role of Inhaled Corticosteroids Paul M. O Byrne, MB, FRCPI, FRCPC, FCCP Frederick E. Hargreave, MD, FRCPC, FRCP Glucocorticosteroids have been used to treat a variety of airway diseases since

More information

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center

More information

PRODUCT INFORMATION (This PI contains all registered presentations of Avamys.) AVAMYS Nasal Spray

PRODUCT INFORMATION (This PI contains all registered presentations of Avamys.) AVAMYS Nasal Spray PRODUCT INFORMATION (This PI contains all registered presentations of Avamys.) AVAMYS Nasal Spray NAME OF THE MEDICINE: Fluticasone furoate Structure: 21 F O 2 3 28 HO 19 1 10 5 4 O 20 S 18 12 O 11 13

More information

Buy full version here - for $ 7.00

Buy full version here - for $ 7.00 This is a Sample version of the Inhaled Corticosteroid Questionnaire (ICQ) The full version of watermark.. the ICQ comes without sample The full complete ICQ Overview information 24 page version includes

More information

Heroin. How is Heroin Abused? What Other Adverse Effects Does Heroin Have on Health? How Does Heroin Affect the Brain?

Heroin. How is Heroin Abused? What Other Adverse Effects Does Heroin Have on Health? How Does Heroin Affect the Brain? Heroin Heroin is a synthetic opiate drug that is highly addictive. It is made from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears

More information

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour. Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,

More information

Medications. Patient Education Pulmonary Rehabilitation. A guide to medications for Chronic Obstructive Pulmonary Disease (COPD) Introduction

Medications. Patient Education Pulmonary Rehabilitation. A guide to medications for Chronic Obstructive Pulmonary Disease (COPD) Introduction Patient Education A guide to medications for Chronic Obstructive Pulmonary Disease (COPD) Do you know how each of your inhalers works to help your breathing? Do you know the correct order in which to use

More information

Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor)

Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor) EMA/662624/2015 Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor) This is a summary of the risk management plan (RMP) for Orkambi, which details the measures to be taken

More information

Dear Provider: Sincerely,

Dear Provider: Sincerely, Asthma Toolkit Dear Provider: L.A. Care is pleased to present this updated asthma toolkit. Our goal is to promote the highest level of asthma care, based on the 2007 National Asthma Education and Prevention

More information

Vitamin D Deficiency and Thyroid Disease. Theodore C. Friedman, M.D., Ph.D.

Vitamin D Deficiency and Thyroid Disease. Theodore C. Friedman, M.D., Ph.D. Vitamin D Deficiency and Thyroid Disease Theodore C. Friedman, M.D., Ph.D. Vitamin D deficiency and thyroid diseases Vitamin D is an important vitamin that not only regulates calcium, but also has many

More information

Forced vital capacity: maximal volume of air exhaled with maximally forced effort from a maximal inspiration.

Forced vital capacity: maximal volume of air exhaled with maximally forced effort from a maximal inspiration. SOP Spirometry 1. General considerations Spirometry serves as a physiological test to quantify pulmonary disease severity and to assess clinical change in respiratory function over time. Standard spirometric

More information

CCHCS Care Guide: Asthma

CCHCS Care Guide: Asthma GOALS SHORTNESS OF BREATH, WHEEZE, COUGH NIGHT TIME AWAKENINGS ACTIVITY INTERFERENCE SABA* USE FOR SYMPTOM CONTROL FEV1* OR PEAK FLOW EXACERBATIONS REQUIRING ORAL STEROIDS < 2 DAYS / WEEK 2 TIMES / MONTH

More information